NVCR Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -40.88% compared to NovoCure's net margin of --. NovoCure's return on equity of -46.72% beat Perspective Therapeutics's return on equity of --.

NovoCure has a consensus price target of $35.57, signalling upside risk potential of 72.51%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.04 which suggests that it could grow by 503.07%. Given that Perspective Therapeutics has higher upside potential than NovoCure, analysts believe Perspective Therapeutics is more attractive than NovoCure.

NovoCure has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $161.3M, which are larger than Perspective Therapeutics quarterly revenues of --. NovoCure's net income of -$65.9M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, NovoCure's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.68x versus 14.36x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -40.88% compared to NovoCure's net margin of -58.2%. NovoCure's return on equity of -46.72% beat Masimo's return on equity of -23.05%.

NovoCure has a consensus price target of $35.57, signalling upside risk potential of 72.51%. On the other hand Masimo has an analysts' consensus of $193.76 which suggests that it could grow by 15.56%. Given that NovoCure has higher upside potential than Masimo, analysts believe NovoCure is more attractive than Masimo.

NovoCure has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison Masimo has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.537%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $161.3M, which are smaller than Masimo quarterly revenues of $600.7M. NovoCure's net income of -$65.9M is higher than Masimo's net income of -$349.6M. Notably, NovoCure's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.68x versus 4.33x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -40.88% compared to NovoCure's net margin of -1226.82%. NovoCure's return on equity of -46.72% beat VolitionRX's return on equity of --.

NovoCure has a consensus price target of $35.57, signalling upside risk potential of 72.51%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 496%. Given that VolitionRX has higher upside potential than NovoCure, analysts believe VolitionRX is more attractive than NovoCure.

NovoCure has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $161.3M, which are larger than VolitionRX quarterly revenues of $474.5K. NovoCure's net income of -$65.9M is lower than VolitionRX's net income of -$5.8M. Notably, NovoCure's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.68x versus 36.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -40.88% compared to NovoCure's net margin of -10.04%. NovoCure's return on equity of -46.72% beat Xtant Medical Holdings's return on equity of -35.34%.

NovoCure has a consensus price target of $35.57, signalling upside risk potential of 72.51%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 259.34%. Given that Xtant Medical Holdings has higher upside potential than NovoCure, analysts believe Xtant Medical Holdings is more attractive than NovoCure.

NovoCure has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $161.3M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. NovoCure's net income of -$65.9M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, NovoCure's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.68x versus 0.56x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.